The use of such a regimen is still the gold standard for first-line treatment of fit patients with CLL, despite new forms of targeted treatment, such as oral tyrosine kinase inhibitors and BCL-2 protein antagonists. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.